Stock 22UA BIONTECH SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials BioNTech SE Börse Stuttgart

Equities

22UA

US09075V1026

Biotechnology & Medical Research

Market Closed - Börse Stuttgart
Other stock markets
 01:26:13 2024-05-03 pm EDT 		5-day change 1st Jan Change
85.95 EUR +0.35% Intraday chart for BioNTech SE +4.63% -3.17%
May. 01 European Equities Traded in the US as American Depositary Receipts Trend Modestly Lower in Wednesday Trading MT
Apr. 25 Sector Update: Health Care Stocks Drop in Afternoon Trading MT

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 6,837 16,071 54,764 34,112 22,730 20,743 - -
Enterprise Value (EV) 1 6,318 14,964 53,372 20,449 22,730 6,708 7,316 8,267
P/E ratio -35.6 x 1,112 x 5.72 x 3.72 x 25 x -36.7 x -36.4 x -30.9 x
Yield - - - - - - - -
Capitalization / Revenue 63 x 33.3 x 2.89 x 1.97 x 5.95 x 7.44 x 7.62 x 7.52 x
EV / Revenue 58.2 x 31 x 2.81 x 1.18 x 5.95 x 2.41 x 2.69 x 3 x
EV / EBITDA -42.8 x -343 x 3.47 x 1.6 x 26 x -10.3 x -9.55 x -9.31 x
EV / FCF -26.6 x -188 x 72.5 x 1.55 x - 29 x -9.6 x -8.04 x
FCF Yield -3.75% -0.53% 1.38% 64.6% - 3.44% -10.4% -12.4%
Price to Book 13.9 x 11.8 x 4.62 x 1.7 x - 1.02 x 1.05 x 1.11 x
Nbr of stocks (in thousands) 226,262 240,786 241,521 243,019 237,716 240,990 - -
Reference price 2 30.22 66.74 226.7 140.4 95.62 86.07 86.07 86.07
Announcement Date 3/31/20 3/30/21 3/30/22 3/27/23 3/20/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 108.6 482.3 18,977 17,311 3,819 2,789 2,722 2,759
EBITDA 1 -147.6 -43.67 15,359 12,766 873.8 -648.5 -766.3 -888.2
EBIT 1 -181.5 -82.42 15,284 12,643 690.4 -877.8 -942.7 -1,032
Operating Margin -167.16% -17.09% 80.54% 73.03% 18.08% -31.47% -34.63% -37.38%
Earnings before Tax (EBT) 1 -179.4 -145.8 15,046 12,954 1,186 -731.4 -639.7 -696.7
Net income 1 -179.1 15.2 10,292 9,434 930.3 -561.9 -528.8 -665.6
Net margin -164.89% 3.15% 54.24% 54.5% 24.36% -20.15% -19.43% -24.12%
EPS 2 -0.8500 0.0600 39.63 37.77 3.830 -2.345 -2.364 -2.787
Free Cash Flow 1 -237.1 -79.51 735.7 13,214 - 231.1 -761.7 -1,028
FCF margin -218.37% -16.48% 3.88% 76.34% - 8.28% -27.99% -37.25%
FCF Conversion (EBITDA) - - 4.79% 103.51% - - - -
FCF Conversion (Net income) - - 7.15% 140.06% - - - -
Dividend per Share 2 - - - - - - - -
Announcement Date 3/31/20 3/30/21 3/30/22 3/27/23 3/20/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 6,087 5,532 6,375 3,196 3,461 4,278 1,277 167.7 895.3 1,479 372.3 158.2 705.5 1,536 97.2
EBITDA 1 4,743 4,726 - - 2,421 3,322 685.8 - 114.4 605 -585 -660 -290 824 -
EBIT 1 4,724 4,700 4,753 2,210 2,388 3,293 654.4 -563.3 73.1 526.2 -445.7 -637.5 -246 387.5 -803.7
Operating Margin 77.6% 84.95% 74.56% 69.13% 68.98% 76.97% 51.25% -335.9% 8.16% 35.58% -119.73% -402.95% -34.87% 25.23% -826.88%
Earnings before Tax (EBT) 1 4,667 4,714 5,018 2,319 2,444 3,173 707.7 -412.2 227.4 663.2 -398.2 -574.5 -193 558.4 -
Net income 1 3,211 3,166 3,699 1,672 1,785 2,279 502.2 -190.4 160.6 457.9 -356.6 -527.2 -178.3 506.6 -
Net margin 52.75% 57.23% 58.02% 52.31% 51.57% 53.26% 39.33% -113.54% 17.94% 30.96% -95.78% -333.25% -25.27% 32.99% -
EPS 2 12.35 12.18 14.24 6.450 6.980 9.260 2.050 -0.7900 0.6700 1.900 -1.531 -1.891 -0.6931 1.593 -1.504
Dividend per Share 2 - - - - - - - - - - - - - - -
Announcement Date 11/9/21 3/30/22 5/9/22 8/8/22 11/7/22 3/27/23 5/8/23 8/7/23 11/6/23 3/20/24 - - - - -
1EUR in Million2EUR
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - - - -
Net Cash position 1 519 1,107 1,391 13,663 - 14,035 13,427 12,475
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 -237 -79.5 736 13,214 - 231 -762 -1,028
ROE (net income / shareholders' equity) -47.1% 1.63% 155% 59.1% - -1.46% -2.27% -3.54%
ROA (Net income/ Total Assets) -24.7% 0.98% 113% 48.2% - -1.69% -2.65% -3.75%
Assets 1 725.3 1,558 9,075 19,555 - 33,207 19,928 17,744
Book Value Per Share 2 2.180 5.680 49.00 82.50 - 84.30 81.90 77.50
Cash Flow per Share 2 -0.9400 -0.0500 3.430 55.80 - 1.260 -1.740 0.0500
Capex 1 38.6 66 128 329 - 434 352 333
Capex / Sales 35.54% 13.69% 0.67% 1.9% - 15.58% 12.92% 12.07%
Announcement Date 3/31/20 3/30/21 3/30/22 3/27/23 3/20/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for BioNTech SE

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
86.07 EUR
Average target price
107 EUR
Spread / Average Target
+24.34%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+313.59% 8.49B
LEGEND BIOTECH CORPORATION Stock Legend Biotech Corporation
-24.53% 8.26B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. BNTX Stock
  4. 22UA Stock
  5. Financials BioNTech SE